Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lack of funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Beaufort | UNKNOWN |
Not provided
Not provided
This study is conducted to evaluate the performance of a rapid, point-of-care in vitro diagnostic device (Sinu-Test®) for the qualitative detection of the three most common pathogens responsible for causing bacterial sinusitis.
Mucous specimens will be collected from patients displaying symptoms of acute bacterial sinusitis enrolled by primary care and/or otolaryngology clinics in the United States. Health care professionals not having endoscopy certification will collect specimens using the Entvantage sample collection device. Health care professionals with nasal endoscopy certification or specialty training will collect comparator specimens using an endoscope. Untrained operators with a range of education and training (primary care physician, otolaryngologist, physician assistant, nurse practitioner, registered nurse or other healthcare professional), will perform the Sinu-Test® lateral flow assay in an outpatient setting. Mucous samples will be tested for the presence of 3 bacterial pathogens responsible for sinusitis using the Sinu-Test® in the clinic and by a composite comparator method comprised of standard quantitative bacterial culture with identification (matrix-assisted laser desorption/ionization-Time of Flight (MALDI-TOF) mass spectrometry instrument) and semiquantitative real-time polymerase chain reaction (real-time PCR) of the residual culture sample and the Sinu-Test® residual swab performed by a central laboratory.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Symptomatic for bacterial sinusitis | Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| rapid in vitro diagnostic test | Diagnostic Test | IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae) |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity (positive predictive agreement) and specificity (negative predictive agreement) of the diagnostic device | Assessment of the true positive and true negative rate of the point-of-care test device relative to the composite reference standard for each of the 3 bacterial microorganisms. | Cumulation of one-time subject sample results obtained in 20-30 minutes for point-of-care test and 3-5 days for lab results |
| Measure | Description | Time Frame |
|---|---|---|
| Positive predictive value (PPV) and negative predictive value (NPV) | Positive predictive value is the probability that subjects with a positive point-of-care test truly have the bacteria present. Negative predictive value is the probability that subjects with a negative point-of-care test truly do not have the bacteria present. | Cumulation of one-time subject sample results obtained in 20-30 minutes for point-of-care test and 3-5 days for lab results |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Chronic sinusitis
Cystic fibrosis
Patients treated with antibiotics currently or within the previous 30 days.
Subjects with a prior history of sinus surgery will be excluded due to the modification of sinonasal anatomy.
Primary immunodeficiencies, as self-reported
Acquired immunodeficiencies, as self-reported
Cognitive impairment resulting in the inability to provide informed consent.
Special groups, such as children under the age of 18, and men and women who are in prison will not participate in this study.
Not provided
Not provided
Not provided
Patients at least 18 years of age with symptoms of bacterial sinusitis from primary care clinics and otolaryngology clinics.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Karen Busch | Beaufort | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Northern California Research | Sacramento | California | 95821 | United States | ||
| Hillcrest Medical Research |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
nasal mucus in buffer solution
|
| bacterial culture | Diagnostic Test | Quantitative bacterial culture assay with isolate identification by MALDI-TOF. |
|
| PCR assay | Diagnostic Test | Semiquantitative real-time PCR assay |
|
| Positive likelihood ratio (LR+) and negative likelihood ratio (LR-) | LR+ is equivalent to the probability of a true positive result divided by the probability of a false positive result. LR- is equivalent to the probability of a false negative result divided by the probability of a true negative result. | Cumulation of one-time subject sample results obtained in 20-30 minutes for point-of-care test and 3-5 days for lab results |
| DeLand |
| Florida |
| 32720 |
| United States |
| ENT Allergy & Associates of South Florida | Port Saint Lucie | Florida | 34952 | United States |
| Tandem Clinical Research | Marrero | Louisiana | 70072 | United States |
| Northwell Health | New Hyde Park | New York | 11042 | United States |
| Optimed Research/Ohio Sinus Institute | Dublin | Ohio | 43016 | United States |
| Kelsey-Seybold Clinic | Houston | Texas | 77025 | United States |